2026 / 02

Следующая статья
DOI: 10.24075/dc.2026.006
Авторские права: © 2026 принадлежат авторам. Лицензиат: РНИМУ им. Н.И. Пирогова.
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).

ОБЗОР

Борсодержащие соединения в медицинской химии: аминоборановые аддукты

Т. А. Копылова1,2 , А. С. Соколова1 , О. И. Яровая1 , Н. Ф. Салахутдинов1
Информация об авторах

1 Новосибирский институт органической химии им. Н. Н. Ворожцова (НИОХ СО РАН), Новосибирск, Россия

2 Новосибирский государственный университет, Новосибирск, Россия

Для корреспонденции: Ольга Ивановна Яровая
Пр. Ак. Лаврентьева, д. 9, г. Новосибирск, 630090, Россия; ur.relbmar@rayo

Статья получена: 29.12.2025 Статья принята к печати: 07.05.2026 Опубликовано online: 30.05.2026
|
  1. Chellan P, Sadler PJ. The elements of life and medicines. Phil Trans R Soc A. 2015; 373 (2037): 20140182. PubMed PMID: 25666066.
  2. Grams RJ, Santos WL, Scorei IR, Abad-García A, Rosenblum CA, Bita A, et al. The rise of boron-containing compounds: advancements in synthesis, medicinal chemistry, and emerging pharmacology. Chem Rev. 2024; 124 (5): 2441–511.
  3. Xiao YC, Yu JL, Dai QQ, Li G, Li GB. Targeting metalloenzymes by boron-containing metal-binding pharmacophores. J Med Chem. 2021; 64 (24): 17706–27.
  4. Fernandes GFS, Denny WA, Dos Santos JL. Boron in drug design: recent advances in the development of new therapeutic agents. Eur J Med Chem. 2019; 179: 791–804.
  5. Baker SJ, Ding CZ, Akama T, Zhang YK, Hernandez V, Xia Y. Therapeutic potential of boron-containing compounds. Future Med Chem. 2009; 1 (7): 1275–88.
  6. Das BC, Nandwana NK, Das S, Nandwana V, Shareef MA, Das Y, et al. Boron chemicals in drug discovery and development: synthesis and medicinal perspective. Molecules. 2022; 27 (9): 2615.
  7. Soriano-Ursúa MA, Das BC, Trujillo-Ferrara JG. Boron-containing compounds: chemico-biological properties and expanding medicinal potential in prevention, diagnosis and therapy. Expert Opin Ther Pat. 2014; 24 (5): 485–500.
  8. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006; 12 (10): 2955–60.
  9. Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016; 4 (4): CD010816.
  10. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14 (3): 451–6.
  11. Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018; 87: 697–724.
  12. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011; 12 (67): 471–80.
  13. Shirley M. Ixazomib: first global approval. Drugs. 2016; 76 (3): 405–11.
  14. Perbandt M, Werner N, Prester A, Rohde H, Aepfelbacher M, Hinrichs W, et al. Structural basis to repurpose boron-based proteasome inhibitors bortezomib and ixazomib as β-lactamase inhibitors. Sci Rep. 2022; 12 (1): 5510.
  15. Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K. Clinical pharmacology of ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet. 2019; 58 (4): 431–49.
  16. Elewski BE, Tosti A. Tavaborole for the treatment of onychomycosis. Expert Opin Pharmacother. 2014; 15 (10): 1439–48.
  17. Cusack S, Yaremchuk A, Tukalo M. The 2 Å crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. EMBO J. 2000; 19 (10): 2351–61.
  18. Das BC, Shareef MA, Das S, Nandwana NK, Das Y, Saito M, et al. Boron-containing heterocycles as promising pharmacological agents. Bioorg Med Chem. 2022; 63: 116748.
  19. Paton DM. Crisaborole: phosphodiesterase inhibitor for treatment of atopic dermatitis. Drugs Today (Barc). 2017; 53 (4): 239–45.
  20. Messner K, Vuong B, Tranmer GK. The boron advantage: the evolution and diversification of boron’s applications in medicinal chemistry. Pharmaceuticals (Basel). 2022; 15 (3): 264.
  21. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg. Med. Chem. Lett. 2009; 19 (8): 2129–32.
  22. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61 (11): e01443–17.
  23. Tsivkovski R, Lomovskaya O. Biochemical activity of vaborbactam. Antimicrob Agents Chemother. 2020; 64 (2): e01935–19.
  24. Гринвуд Н., Эрншо А. Химия элементов. М.: Лаборатория знаний, 2008. Т. 1. 607 с.
  25. Banu T, Sen K, Ghosh D, Debnath T, Das AK. Cyclic amine-borane adducts [CnH2n+1N·BH3 (n = 2–6)] as chemical hydrogen storage systems: a computational analysis. RSC Adv. 2014; 4 (3): 1352–61.
  26. Staubitz A, Robertson APM, Sloan ME, Manners I. Amine- and phosphine-borane adducts: new interest in old molecules. Chem Rev. 2010; 110 (7): 4023–78.
  27. Burnham BS. Synthesis and pharmacological activities of amine-boranes. Curr Med Chem. 2005; 12 (17): 1995–2010.
  28. Sood CK, Sood A, Spielvogel BF, Yousef JA, Burnham B, Hall IH. Synthesis and antineoplastic activity of some cyano-, carboxy-, carbomethoxy-, and carbamoylborane adducts of heterocyclic amines. J Pharm Sci. 1991; 80 (12): 1133–40.
  29. Sood A, Sood CK, Spielvogel BF, Hall IH. Boron analogues of amino acids VI. Synthesis and characterization of di- and tripeptide analogues as antineoplastic, anti-inflammatory and hypolipidemic agents. Eur J Med Chem. 1990; 25 (4): 301–8.
  30. Rajendran KG, Burnham BS, Chen SY, Sood A, Spielvogel BF, Shaw BR, et al. Anti-inflammatory and anti-osteoporotic activities of base-boronated nucleosides and phosphate-boronated nucleotides in rodents. J Pharm Sci. 1994; 83 (10): 1391–5.
  31. Yang F, Zhu M, Zhang J, Zhou H. Synthesis of biologically active boron-containing compounds. Med Chem Commun. 2018; 9 (2): 201–11.
  32. Khaliq H. Exploring the role of boron-containing compounds in biological systems: potential applications and key challenges. J Trace Elem Med Biol. 2025; 81: 127594.
  33. Diaz DB, Yudin AK. The versatility of boron in biological target engagement. Nat Chem. 2017; 9 (8): 731–42.